What is Alvotech?
Founded in 2013 and headquartered in Luxembourg, Alvotech specializes in the development and manufacturing of high-quality biosimilar medicines. The company occupies a critical niche in the pharmaceutical industry, providing cost-effective alternatives to complex biologic drugs. Its diverse pipeline includes advanced programs such as AVT02, a biosimilar to Humira, and AVT04, targeting Stelara, alongside a broad range of candidates addressing inflammatory conditions and bone disorders. By integrating research, development, and large-scale production, Alvotech positions itself as a vital partner in improving patient access to essential therapies worldwide.
How much funding has Alvotech raised?
Alvotech has raised a total of $928.2M across 8 funding rounds:
Other Financing Round
$300M
Share Placement
$35M
Multiple Rounds
$136M
Debt
$100M
Debt
$117.2M
Debt
$75M
Other Financing Round (2019): $300M with participation from Fuji Pharma
Share Placement (2021): $35M led by ATHOS, Shinhan Financial Group, and Baxter Healthcare
Debt (2022): $50M supported by Alvogen
Debt (2022): $16M featuring Landsbankinn HF
Debt (2022): $70M backed by Morgan Stanley, Oaktree, Sculptor Capital, and Farallon Capital Management
Debt (2023): $100M with participation from At&p Holding
Debt (2026): $117.2M led by GoldenTree Asset Management
Debt (2026): $75M supported by GoldenTree Asset Management
Key Investors in Alvotech
Fuji Pharma
A Japanese pharmaceutical firm focused on the development and marketing of new drugs, generics, and biosimilars, with a strong emphasis on women's healthcare and acute medical care.
GoldenTree Asset Management
A global, employee-owned credit asset management firm that specializes in high-yield bonds, private credit, and distressed debt strategies across diverse sectors.
Shinhan Financial Group
A comprehensive Asian financial services organization providing a wide range of banking, investment, and wealth management solutions to global clients.
What's next for Alvotech?
Looking ahead, Alvotech is poised to leverage its recent capital infusion to accelerate the commercialization of its late-stage pipeline, including AVT23 and AVT33. The strategic focus remains on expanding its global footprint and optimizing manufacturing efficiencies to meet the rising demand for biosimilars. As the company moves deeper into its lifecycle, the emphasis will likely shift toward market penetration and the successful execution of its regulatory milestones, further solidifying its competitive advantage in the global healthcare market.
See full Alvotech company page
